BRAF and synovial sarcoma: Treatment of BRAF<sup>V600E</sup> synovial sarcoma with dabrafenib & trametinib can lead to complete pathological response and prolonged radiological response, as well as the rare adverse event of hemophagocytic lymphohistiocytosis.